143 related articles for article (PubMed ID: 2329214)
1. A study of systemic and topical effects of topical steroid application through the comparison of two application schedules.
Fukaya Y; Masutani M; Koyama Y; Takahashi H; Ueda H
J Dermatol; 1990 Jan; 17(1):28-33. PubMed ID: 2329214
[TBL] [Abstract][Full Text] [Related]
2. Methods for the assessment of skin atrophogenicity of topical corticosteroids.
Marks R
Dermatologica; 1976; 152 Suppl 1():117-26. PubMed ID: 133834
[TBL] [Abstract][Full Text] [Related]
3. Effect of glucocorticosteroids on epidermal Langerhans cells.
Belsito DV; Flotte TJ; Lim HW; Baer RL; Thorbecke GJ; Gigli I
J Exp Med; 1982 Jan; 155(1):291-302. PubMed ID: 6459400
[TBL] [Abstract][Full Text] [Related]
4. Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications.
Woodford R; Haigh JM; Barry BW
Dermatologica; 1983; 166(3):136-40. PubMed ID: 6852325
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological evaluation of a new topical preparation containing dextran sulphate and betamethasone 17-valerate.
Passarella E; Milanino R
Arzneimittelforschung; 1980; 30(4):647-51. PubMed ID: 6156688
[TBL] [Abstract][Full Text] [Related]
6. Topical betamethasone 17-valerate is an anticorticosteroid in the rat. 1. Dermal atrophy.
Young JM; Yoxall BE; Wagner BM
Br J Dermatol; 1978 Dec; 99(6):655-63. PubMed ID: 737128
[TBL] [Abstract][Full Text] [Related]
7. Local tolerability of topically applied methylprednisolone aceponate.
Kecskés A; Jahn P; Lange L
J Am Acad Dermatol; 1993 May; 28(5 Pt 1):786-8. PubMed ID: 8496430
[No Abstract] [Full Text] [Related]
8. Plasma cortisol levels in normal volunteers receiving either betamethasone valerate or desoximetasone by topical application.
Bromley PA; Müller FO; Malan J; Torres J; Vanderbeke O
S Afr Med J; 1978 Aug; 54(6):239-41. PubMed ID: 362568
[TBL] [Abstract][Full Text] [Related]
9. Steroid-induced atrophy in an animal and human model.
Kirby JD; Munro DD
Br J Dermatol; 1976 Mar; 94 suppl 12():111-9. PubMed ID: 1268071
[TBL] [Abstract][Full Text] [Related]
10. Induction of lipocortin 1 by topical steroid in rat skin.
Ahluwalia A; Mohamed RW; Flower RJ
Biochem Pharmacol; 1994 Oct; 48(8):1647-54. PubMed ID: 7980630
[TBL] [Abstract][Full Text] [Related]
11. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
Szadurski J; Renz F; Gasser D
Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
[TBL] [Abstract][Full Text] [Related]
12. Topical glucocorticoids of the non-fluorinated double-ester type. Lack of atrophogenicity in normal skin as assessed by high-frequency ultrasound.
Kerscher MJ; Korting HC
Acta Derm Venereol; 1992; 72(3):214-6. PubMed ID: 1357864
[TBL] [Abstract][Full Text] [Related]
13. Topical betamethasone 17-valerate is an anticorticosteroid in the rat. 2. Anti-inflammatory and anti-lymphocyte activities.
Young JM; Wagner BM; Fisk RA
Br J Dermatol; 1978 Dec; 99(6):665-73. PubMed ID: 737129
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry.
Bjerring P
Skin Pharmacol; 1993; 6(3):187-92. PubMed ID: 8274288
[TBL] [Abstract][Full Text] [Related]
15. The effect of topical steroid application on natural killer cell activity.
Lesko MJ; Lever RS; Mackie RM; Parrott DM
Clin Exp Allergy; 1989 Nov; 19(6):633-6. PubMed ID: 2598103
[TBL] [Abstract][Full Text] [Related]
16. A double-blind comparison of 1% hydrocortisone plus 10% urea ('Alphaderm') and 0.1% betamethasone 17-valerate in the treatment of non-infective inflammatory dermatoses.
Khan SA; Williamson DM
Curr Med Res Opin; 1977-1978; 5(4):354-8. PubMed ID: 343995
[TBL] [Abstract][Full Text] [Related]
17. Once daily application of diflorasone diacetate ointment compared with betamethasone valerate ointment twice daily in patients with eczematous dermatoses.
Hersle K; Mobacken H
J Int Med Res; 1982; 10(6):423-5. PubMed ID: 7152081
[TBL] [Abstract][Full Text] [Related]
18. Assessment of some variables affecting the blanching activity of betamethasone 17-valerate cream.
Magnus AD; Haigh JM; Kanfer I
Dermatologica; 1980; 160(5):321-7. PubMed ID: 7364141
[TBL] [Abstract][Full Text] [Related]
19. Topical betamethasone-17-valerate inhibits heat-induced vasodilatation in man.
Ahluwalia A; Flower RJ
Br J Dermatol; 1993 Jan; 128(1):45-8. PubMed ID: 8427821
[TBL] [Abstract][Full Text] [Related]
20. Plasma concentrations of betamethasone after topical application of betamethasone 17-valerate: comparison with oral administration.
Kubota K; Lo ES; Huttinot G; Andersen PH; Maibach HI
Br J Clin Pharmacol; 1994 Jan; 37(1):86-8. PubMed ID: 8148226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
